These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 4551793)

  • 41. Endothelin-1 and cold provocation in health, primary Raynaud's phenomenon, and progressive systemic sclerosis.
    Dörffler-Melly J; Lüscher TF; Wenk M; Wen S; Bollinger A; Franzeck UK
    Microvasc Res; 1996 Sep; 52(2):193-7. PubMed ID: 8901448
    [No Abstract]   [Full Text] [Related]  

  • 42. [Raynaud's phenomenon: evolution of the concepts].
    Vayssairat M; Baudot N
    Vasa Suppl; 1989; 27():31-2. PubMed ID: 2623522
    [No Abstract]   [Full Text] [Related]  

  • 43. On surgical microarteriolysis for treatment of Raynaud's phenomenon in scleroderma.
    van den Broeck D; Coessens BC; Peretz A
    Br J Rheumatol; 1997 Jun; 36(6):706-7. PubMed ID: 9236686
    [No Abstract]   [Full Text] [Related]  

  • 44. Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry.
    Delisle VC; Hudson M; Baron M; Thombs BD; And The Canadian Scleroderma Research Group A
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-10-4. PubMed ID: 24144459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Scleroderma and Raynaud's phenomenon.
    BARNETT AJ
    Clin Rep; 1959; 9():33-74. PubMed ID: 13796900
    [No Abstract]   [Full Text] [Related]  

  • 46. [Collagenoses and Raynaud's phenomenon].
    Guillaume JC; Touraine R
    Rev Prat; 1981 Dec; 31(55):4027-8 passim. PubMed ID: 7313482
    [No Abstract]   [Full Text] [Related]  

  • 47. Raynaud's phenomenon and Raynaud's disease definition of Raynaud's phenomenon.
    Pratesi F; Corsi C; Deidda C; Nuti A
    Schweiz Rundsch Med Prax; 1976 Nov; 65(44):1368-70. PubMed ID: 1005332
    [No Abstract]   [Full Text] [Related]  

  • 48. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.
    Reilly IA; Roy L; Fitzgerald GA
    Br Med J (Clin Res Ed); 1986 Apr; 292(6527):1037-9. PubMed ID: 3083991
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Topical Rosmarinus officinalis L. in Systemic Sclerosis-Related Raynaud's Phenomenon: An Open-Label Pilot Study.
    Vagedes J; Henes J; Deckers B; Vagedes K; Kuderer S; Helmert E; von Schoen-Angerer T
    Complement Med Res; 2022; 29(3):242-248. PubMed ID: 35139518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Digital sympathectomy (microarteriolysis) in the treatment of severe Raynaud's phenomenon secondary to systemic sclerosis.
    Hafner J; Della Santa D; Zuber C; Christen Y; Bounameaux H
    Br J Dermatol; 1997 Dec; 137(6):1019-20. PubMed ID: 9470932
    [No Abstract]   [Full Text] [Related]  

  • 54. [Idiopathic and secondary Raynaud's phenomenon. A comparative psychosomatic approach].
    Bayle O; Consoli SM; Baudin M; Vayssairat M; Fiessinger JN; Housset E
    Presse Med; 1990 Apr; 19(16):741-5. PubMed ID: 2140158
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Raynaud's phenomenon and systemic diseases: immunological viewpoint].
    Lantin JP; Duc J
    Rev Med Suisse Romande; 1992 May; 112(5):401-4. PubMed ID: 1604100
    [No Abstract]   [Full Text] [Related]  

  • 56. [Rheology of giant capillary occlusion in secondary Raynaud's phenomenon within the scope of systemic sclerosis].
    Schmid-Schönbein H; Goebel W; Perkkiö J; Polster H; Jacobs M; Lemmens HA
    Vasa Suppl; 1989; 27():61-3. PubMed ID: 2623545
    [No Abstract]   [Full Text] [Related]  

  • 57. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension.
    Wigley FM
    Curr Opin Rheumatol; 1996 Nov; 8(6):561-8. PubMed ID: 9018460
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spontaneous neutrophil activation in patients with primary Raynaud's phenomenon and systemic sclerosis.
    Stevens TR; Hall ND; McHugh NJ; Maddison PJ
    Br J Rheumatol; 1992 Dec; 31(12):856. PubMed ID: 1458295
    [No Abstract]   [Full Text] [Related]  

  • 59. [Retroperitoneal fibrosis and generalized scleroderma].
    Cochat P; Colon S; Laville M; Maillet P; Lefrançois N; Moskovtchenko JF; Traeger J
    Nephrologie; 1985; 6(1):27-30. PubMed ID: 4000379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circulating nerve growth factor in primary and secondary Raynaud's syndrome - results of a pilot study.
    Klein-Weigel P; Gutsche-Petrak B; Humpel C; Riemekasten G; Ivanov S; Heidrich H
    Vasa; 2009 Feb; 38(1):39-45. PubMed ID: 19229802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.